Novavax Inc.
8.53
-0.08 (-0.87%)
At close: Jan 14, 2025, 3:59 PM
8.53
0.05%
Pre-market Jan 15, 2025, 06:53 AM EST
undefined%
Bid 8.52
Market Cap 1.37B
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -2.18
PE Ratio (ttm) -3.91
Forward PE n/a
Analyst Buy
Ask 8.63
Volume 2,341,192
Avg. Volume (20D) 5,293,659
Open 8.77
Previous Close 8.61
Day's Range 8.40 - 8.79
52-Week Range 3.53 - 23.86
Beta undefined

About NVAX

Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical tria...

Industry Biotechnology
Sector Healthcare
IPO Date Dec 5, 1995
Employees 1,543
Stock Exchange NASDAQ
Ticker Symbol NVAX

Analyst Forecast

According to 6 analyst ratings, the average rating for NVAX stock is "Buy." The 12-month stock price forecast is $18.5, which is an increase of 117.00% from the latest price.

Buy 50.00%
Hold 33.33%
Sell 16.67%
Stock Forecasts

Next Earnings Release

Novavax Inc. is scheduled to release its earnings on Feb 26, 2025, before market opens.
Analysts project revenue of $176.05M, reflecting a -39.57% YoY shrinking and earnings per share of -0.29, making a -80.27% decrease YoY.
2 days ago · Source
-7.62%
Shares of vaccine stocks are trading lower after M... Unlock content with Pro Subscription
1 week ago · Source
+10.86%
Shares of vaccine makers are trading higher after the first bird flu death was reporting in the US. Additionally, a recent CDC report noted an increase in acute respiratory illness activity.